These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 31897900

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
    Wen J, Li R, Lu Y, Shupnik MA.
    Oncogene; 2009 Jan 29; 28(4):575-86. PubMed ID: 18997820
    [Abstract] [Full Text] [Related]

  • 3. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.
    J Natl Cancer Inst; 2011 Apr 06; 103(7):538-52. PubMed ID: 21447808
    [Abstract] [Full Text] [Related]

  • 4. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, Liu Q, Hu P, Murphy LC, Raouf A.
    Cell Physiol Biochem; 2018 Apr 06; 51(4):1518-1532. PubMed ID: 30497079
    [Abstract] [Full Text] [Related]

  • 5. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO.
    Mol Cancer; 2013 Feb 04; 12():9. PubMed ID: 23379261
    [Abstract] [Full Text] [Related]

  • 6. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
    Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K.
    Cancer Res; 2018 Feb 01; 78(3):671-684. PubMed ID: 29212856
    [Abstract] [Full Text] [Related]

  • 7. MLL3 is a de novo cause of endocrine therapy resistance.
    Stauffer KM, Elion DL, Cook RS, Stricker T.
    Cancer Med; 2021 Nov 01; 10(21):7692-7711. PubMed ID: 34581028
    [Abstract] [Full Text] [Related]

  • 8. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.
    Breast Cancer Res; 2014 May 28; 16(3):R53. PubMed ID: 24886537
    [Abstract] [Full Text] [Related]

  • 9. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
    Selmin OI, Donovan MG, Skovan B, Paine-Murieta GD, Romagnolo DF.
    Int J Oncol; 2019 Mar 28; 54(3):869-878. PubMed ID: 30664189
    [Abstract] [Full Text] [Related]

  • 10. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS, Li Y, Zhang H, Zhang D, Zhang XB, Wang X, Yu Y.
    Theranostics; 2020 Mar 28; 10(23):10729-10742. PubMed ID: 32929377
    [Abstract] [Full Text] [Related]

  • 11. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.
    Endocr Relat Cancer; 2006 Dec 28; 13(4):1121-33. PubMed ID: 17158758
    [Abstract] [Full Text] [Related]

  • 12. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
    Yu S, Gong X, Ma Z, Zhang M, Huang L, Zhang J, Zhao S, Zhu T, Yu Z, Chen L.
    Cell Oncol (Dordr); 2020 Feb 28; 43(1):65-80. PubMed ID: 31701491
    [Abstract] [Full Text] [Related]

  • 13. Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells.
    Jin ML, Kim YW, Jin HL, Kang H, Lee EK, Stallcup MR, Jeong KW.
    Int J Cancer; 2018 Dec 01; 143(11):2871-2883. PubMed ID: 30191958
    [Abstract] [Full Text] [Related]

  • 14. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA.
    Breast Cancer Res Treat; 2015 Nov 01; 154(2):225-37. PubMed ID: 26487496
    [Abstract] [Full Text] [Related]

  • 15. Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer.
    Poulard C, Ha Pham T, Drouet Y, Jacquemetton J, Surmielova A, Kassem L, Mery B, Lasset C, Reboulet J, Treilleux I, Marangoni E, Trédan O, Le Romancer M.
    EMBO Mol Med; 2023 Aug 07; 15(8):e17248. PubMed ID: 37458145
    [Abstract] [Full Text] [Related]

  • 16. USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα.
    Zhuang T, Zhang S, Liu D, Li Z, Li X, Li J, Yang P, Zhang C, Cui J, Fu M, Shen F, Yuan L, Zhang Z, Su P, Zhu J, Yang H.
    J Exp Clin Cancer Res; 2024 Aug 31; 43(1):249. PubMed ID: 39215346
    [Abstract] [Full Text] [Related]

  • 17. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Gao P, Wang X, Jin Y, Hu W, Duan Y, Shi A, Du Y, Song D, Yang M, Li S, Han B, Zhao G, Zhang H, Fan Z, Miao QR.
    Breast Cancer Res; 2018 Sep 12; 20(1):112. PubMed ID: 30208932
    [Abstract] [Full Text] [Related]

  • 18. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
    Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L.
    Breast Cancer Res Treat; 2011 Jul 12; 128(2):357-68. PubMed ID: 20730598
    [Abstract] [Full Text] [Related]

  • 19. A hidden Markov model to identify combinatorial epigenetic regulation patterns for estrogen receptor α target genes.
    Bonneville R, Jin VX.
    Bioinformatics; 2013 Jan 01; 29(1):22-8. PubMed ID: 23104890
    [Abstract] [Full Text] [Related]

  • 20. IL-1β induced methylation of the estrogen receptor ERα gene correlates with EMT and chemoresistance in breast cancer cells.
    Jiménez-Garduño AM, Mendoza-Rodríguez MG, Urrutia-Cabrera D, Domínguez-Robles MC, Pérez-Yépez EA, Ayala-Sumuano JT, Meza I.
    Biochem Biophys Res Commun; 2017 Aug 26; 490(3):780-785. PubMed ID: 28645612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.